10-Q: Anebulo Pharmaceuticals Reports Q2 2025 Results, Prioritizes IV Selonabant for Pediatric Cannabis Toxicity

Anebulo Pharmaceuticals focuses on developing intravenous selonabant for pediatric cannabis toxicity while reporting a net loss of $4.66 million for the six months ended December 31, 2024.

Summary

• Anebulo Pharmaceuticals, a clinical-stage pharmaceutical company, is focusing on developing treatments for cannabis-induced toxicity.
• The company's lead product candidate, selonabant, is intended to reverse the negative effects of cannabis-induced toxicity.
• Anebulo is prioritizing the advancement of an intravenous (IV) formulation of selonabant for pediatric patients with cannabis-induced CNS depression.
• The company met with the FDA in December 2024 to discuss the development of IV selonabant and plans to begin a Phase I study in healthy adults in the first half of 2025.
• For the six months ended December 31, 2024, Anebulo reported a net loss of $4.66 million, compared to a net loss of $5.19 million for the same period in 2023.
• Research and development expenses for the six months ended December 31, 2024, were $2.54 million, compared to $2.33 million for the same period in 2023.
• General and administrative expenses for the six months ended December 31, 2024, were $2.46 million, compared to $2.97 million for the same period in 2023.
• In December 2024, the company completed a private placement, resulting in net proceeds of approximately $15.0 million.
• The company expects its cash and cash equivalents, along with available funding under the Loan Agreement, will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance date of the financial statements.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, it has made progress in securing funding and advancing its lead product candidate. The focus on pediatric cannabis toxicity and the FDA's positive feedback are also encouraging signs.

Positives

• The company is prioritizing a potentially faster path to approval by focusing on intravenous selonabant for pediatric patients.
• Anebulo received a $1.9 million grant from NIDA to support the development of intravenous selonabant.
• The company completed a private placement, raising $15.0 million in net proceeds.
• The company believes the recent decision by the United States Department of Justice to support the rescheduling of marijuana from a schedule I to a schedule III-controlled substance is a move that will ultimately lead to increased use of cannabis-containing products among US households.

Negatives

• The company has incurred operating losses since inception and expects to continue to incur significant operating losses and negative cash flows from operations in the future.
• Anebulo reported a net loss of $4.66 million for the six months ended December 31, 2024.
• The company has no product revenue and will need to raise additional capital in the future, which may be unavailable or may cause dilution.

Risks

• The company's future success depends on the successful development and commercialization of its product candidates, which is subject to numerous risks and uncertainties.
• Anebulo may be unable to obtain regulatory approval for its product candidates.
• The company faces competition from other companies developing treatments for cannabis-induced toxicity.
• Anebulo may be unable to obtain and maintain adequate intellectual property rights.
• The company is dependent on third-party suppliers and manufacturers.
• The company may be affected by changes in governmental laws and regulations.
• The company may be unable to generate sufficient revenue or cash flow to fund its operations.
• The company may need to curtail its business activities if it is unsuccessful in addressing these risks.

Future Outlook

Anebulo expects its cash and cash equivalents, along with available funding under the Loan Agreement, will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance date of the financial statements. The company plans to begin a Phase I single ascending dose (SAD) study of IV selonabant in healthy adults in 1H25.

Management Comments

• FDA acknowledged the unmet need for a treatment for children exposed to cannabis toxicity, and proposed a close, ongoing collaboration to efficiently advance the selonabant program for the pediatric indication.

Industry Context

Cannabis-induced toxicity has become a widespread health issue in the United States, particularly in states that have legalized cannabis. Hospital emergency rooms across the United States have seen a dramatic increase in patient visits with cannabis-related conditions. The recent decision by the United States Department of Justice to support the rescheduling of marijuana from a schedule I to a schedule III-controlled substance is a move that we believe will ultimately lead to increased use of cannabis-containing products among US households.

Comparison to Industry Standards

• It is difficult to compare Anebulo's results directly to industry standards due to its unique focus on cannabis-induced toxicity and its stage of development.
• Many pharmaceutical companies developing treatments for substance abuse or related conditions, such as Alkermes or Indivior, have broader product portfolios and revenue streams.
• Anebulo's reliance on external funding and its focus on a specific indication make it more comparable to other small, clinical-stage biotech companies.
• The $1.9 million NIDA grant is a positive sign, as government funding is often seen as validation of a company's research and development efforts.
• However, Anebulo's continued operating losses and need for additional funding are typical for companies in this stage, highlighting the inherent risks of drug development.

Related Party Transactions

• On December 22, 2024, the Company entered into a securities purchase agreement with 22NW Fund, LP, a greater than 5% stockholder of the Company that is controlled by Aron English, a director of the Company.

Stakeholder Impact

• Shareholders: The company's focus on IV selonabant and recent funding may be viewed positively, but continued losses and potential dilution remain concerns.
• Employees: The company's ability to continue operations and advance its product candidates depends on securing additional funding.
• Patients: The development of selonabant could provide a much-needed treatment for cannabis-induced toxicity, particularly in children.
• Creditors: The company's ability to repay its debts depends on its ability to generate revenue or secure additional funding.

Next Steps

• Begin a Phase I single ascending dose (SAD) study of IV selonabant in healthy adults in 1H25.
• Continue scaling up the intravenous formulation for initial clinical safety studies.
• Complete IND-enabling activities and the scale up of its formulation of intravenous selonabant around calendar year end 2024.
• Enroll the first healthy adult volunteer in the first half of calendar 2025.

Key Dates